BIOCON.NS - Biocon Limited

NSE - NSE Real Time Price. Currency in INR
643.70
+39.85 (+6.60%)
At close: 3:30PM IST
Stock chart is not supported by your current browser
Previous Close603.85
Open604.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range604.00 - 652.80
52 Week Range295.03 - 652.80
Volume11,193,528
Avg. Volume3,221,286
Market Cap379.197B
BetaN/A
PE Ratio (TTM)85.09
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Bloomberg6 days ago

    Biocon Inks Deal With Novartis After U.S. Nod for Biologic Drug

    Biocon Ltd. said it signed a deal to develop copycat versions of biologic drugs with a unit of Novartis AG, its latest move to become a global player in the next generation of generic medicines after a ...

  • Biocon Limited’s (NSE:BIOCON) Earnings Declined -59.05%, But How Did It Fare Against The Industry?
    Simply Wall St.6 days ago

    Biocon Limited’s (NSE:BIOCON) Earnings Declined -59.05%, But How Did It Fare Against The Industry?

    Measuring Biocon Limited’s (NSEI:BIOCON) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceed expectations, whichRead More...

  • Why Biocon Limited (NSE:BIOCON) Delivered An Inferior ROE Compared To The Industry
    Simply Wall St.25 days ago

    Why Biocon Limited (NSE:BIOCON) Delivered An Inferior ROE Compared To The Industry

    Biocon Limited’s (NSEI:BIOCON) most recent return on equity was a substandard 10.42% relative to its industry performance of 16.12% over the past year. Though BIOCON’s recent performance is underwhelming, itRead More...

  • Reuters29 days ago

    BRIEF-Kelington Group Updates On Application For Enforcement Of Adjudication Decision By Unit

    Dec 26 (Reuters) - Kelington Group Bhd: * UPDATES ON APPLICATION FOR ENFORCEMENT OF ADJUDICATION DECISION BY KELINGTON TECHNOLOGIES SDN BHD AGAINST BIOCON SDN BHD‍​ * HIGH COURT ALLOWED UNIT’S APPLICATION ...

  • Biocon Gets FDA Inspection Clearance for Unit at Bengaluru
    Bloomberg2 months ago

    Biocon Gets FDA Inspection Clearance for Unit at Bengaluru

    Biocon Ltd. has received U.S. Food and Drug Administration clearance for the sterile products unit of its Bengaluru facility, a sign of progress in its bid to bring the plant up to regulatory standards ...

  • Reuters3 months ago

    Biocon second-quarter profit more than halves

    (Reuters) - India's Biocon Ltd posted a 53 percent fall in quarterly profit on Thursday, missing estimates, as higher costs at its Malaysia plant and pricing pressures in its active pharmaceutical ingredients ...

  • Reuters3 months ago

    BRIEF-India's Biocon Sept-qtr consol profit more than halves

    Oct 26 (Reuters) - Biocon Ltd * Sept quarter consol profit 688 million rupees versus 1.47 billion rupees last year * Consensus forecast for Sept quarter consol profit was 1.14 billion rupees * Sept quarter ...

  • Mylan Receives CRL for Neulasta Biosimilar
    GuruFocus.com3 months ago

    Mylan Receives CRL for Neulasta Biosimilar

    Company's co-developer partner has to provide FDA with more data

  • Amgen Wins Reprieve on Its 2nd-Best-Selling Drug
    Motley Fool3 months ago

    Amgen Wins Reprieve on Its 2nd-Best-Selling Drug

    Biosimilar drugmakers are eager to launch competitors to Amgen's drugs, but one big competitor is going to have to wait a while longer.

  • Reuters7 months ago

    FDA rejects Coherus's biosimilar for Neulasta, shares plunge

    Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its biosimilar copy of Amgen Inc's blockbuster treatment, Neulasta, which is used to fight infections in cancer patients. Shares of Coherus tumbled 30 percent to $14.47 in morning trading, while Amgen's shares were up slightly at $164.19.

  • Reuters9 months ago

    India watchdog orders antitrust probe into Roche cancer drug

    India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients. Trastuzumab has been a mainstay of Roche's profit for years and brought in global sales of about $6.7 billion in 2016, but it has been challenged in the last three years by biosimilars which are sold at about a 25 percent discount to the original. India's Biocon and U.S. firm Mylan, which together sell biosimilars of the drug in over a dozen countries including India, filed a complaint with the Competition Commission of India (CCI) last year alleging Roche misled doctors and regulators to thwart competition to trastuzumab.

  • Mylan's Proposed Biosimailar for Cancer Under Review in U.S.
    Zacks11 months ago

    Mylan's Proposed Biosimailar for Cancer Under Review in U.S.

    Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.